PPARA and metabolic dysfunction-associated steatotic liver disease: CPT-1, a target gene of PPARalpha, is the mitochondrial gateway for fatty acid entry into the mitochondrial matrix, being the master regulator of the hepatic mitochondrial beta-oxidation [42], [44], and it was reported that patients with NAFLD presents a decreased expression of CPT-1 gene [45].